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Israel Lopez-Valero3,4, Maria Eleni Anagnostou1, Fiyinfoluwa Babatunde1, Marco Corazzari5,
Christopher P.F. Redfern6, Guillermo Velasco3,4,7 and Penny E. Lovat1,7
Although the global incidence of cutaneous melanoma is increasing, survival rates for patients with metastatic
disease remain o10%. Novel treatment strategies are therefore urgently required, particularly for patients
bearing BRAF/NRAS wild-type tumors. Targeting autophagy is a means to promote cancer cell death in
chemotherapy-resistant tumors, and the aim of this study was to test the hypothesis that cannabinoids promote
autophagy-dependent apoptosis in melanoma. Treatment with Δ9-Tetrahydrocannabinol (THC) resulted in the
activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine
or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.
Administration of Sativex-like (a laboratory preparation comprising equal amounts of THC and cannabidiol
(CBD)) to mice bearing BRAF wild-type melanoma xenografts substantially inhibited melanoma viability,
proliferation, and tumor growth paralleled by an increase in autophagy and apoptosis compared with standard
single-agent temozolomide. Collectively, our ﬁndings suggest that THC activates noncanonical autophagy-
mediated apoptosis of melanoma cells, suggesting that cytotoxic autophagy induction with Sativex warrants
clinical evaluation for metastatic disease.
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INTRODUCTION
Cutaneous melanoma incidence continues to increase, and
response rates of patients with metastatic melanoma to
current therapy remain poor (Garbe et al., 2011). Identiﬁ-
cation of driver mutations and development of targeted
therapies to BRAF/MEK have revolutionized melanoma
therapy, although clinical resistance is inevitable (Chen and
Davies, 2014). The emergence of immunotherapies that are
able to promote tumor T-cell responses is further changing
melanoma management (Wolchok et al., 2010); however, not
all patients respond (Prieto et al., 2012). It is therefore clear
that there is no consistently beneﬁcial treatment for metastatic
melanoma and alternative approaches should be explored.
Autophagy (macroautophagy) is the principal lysosomal-
mediated mechanism for the degradation of damaged or long-
lived organelles and proteins. Under physiological condi-
tions, autophagy maintains normal turnover of cellular
components, as well as responding to metabolic stress,
whereas in pathological settings autophagy activation med-
iates defense against extracellular insults and pathogens (Choi
et al., 2013). The current model for the role of autophagy in
cancer is that in the early stages of tumor development,
quality control by autophagy inhibits tumorigenesis, whereas
in advanced cancer autophagy provides energy to meet the
increased demands and a means to resist cell death caused by
cytotoxic therapy (White, 2012). Preclinical data suggest that
lysosomal inhibition can cause tumor regression, and the
lysosome inhibitors chloroquine or hydroxychloroquine are
now being evaluated in clinical trials either alone or in com-
bination with chemotherapy (Yang et al., 2011). However,
recent studies suggest that chloroquine/hydroxychloroquine
treatment may promote tumor development (Michaud et al.,
2011; Maycotte et al., 2012), questioning the beneﬁt of
autophagy inhibition. An alternative approach for autophagy
modulation is via exacerbation; although initially this appears
counterintuitive to treat advanced cancer, recent evidence
suggests that in particular circumstances a consequence of
autophagy activation is cell death (Ding et al., 2007; Scarlatti
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et al., 2008; Tomic et al., 2011; Basit et al., 2013).
Therapeutic exploitation of cytotoxic autophagy to drive
cancer cell death is therefore an emerging concept for the
development of novel cancer treatments.
Cannabinoids are a diverse class of compounds derived
from Cannabis sativa, with Δ9-tetrahydrocannabinol (THC)
the most relevant owing to its high potency and abundance
(Pertwee, 2008). THC exerts its biological effects by mimick-
ing endocannabinoids that bind to and activate two G
protein–coupled cannabinoid receptors: CB1 and CB2
(Howlett et al., 2002). CB1/CB2 receptors are expressed in
many cancer cell types (Velasco et al., 2012), and cannabi-
noids are currently being investigated as anticancer agents,
including glioblastoma for which THC has shown conside-
rable promise (Velasco et al., 2012). Preclinical data demon-
strate that THC exerts its antitumoral action via induction of
endoplasmic reticulum (ER) stress, upregulation of the
transcriptional coactivator p8 and the pseudo-kinase tribbles
homolog 3 (TRIB3), the stimulation of autophagy, and execu-
tion of apoptosis (Carracedo et al., 2006; Salazar et al., 2009a,
b). Blockade of autophagy prevents THC-induced apoptosis
and cell death, indicating that autophagy is upstream of
apoptosis and demonstrating the potential of p8/TRIB3-
mediated autophagy as a cytotoxic pathway.
Alongside genetic changes, adaption to ER stress and the
aberrant control of autophagy have emerged as key drivers of
malignancy and therapy resistance in advanced mela-
noma (Armstrong et al., 2011; Corazzari et al., 2013). The
cannabinoid receptors have previously been identiﬁed as
potential therapeutic targets (Blazquez et al., 2006; Carracedo
et al., 2006); hence, targeting ER stress responses combined
with cytotoxic autophagy using cannabinoids may represent a
valuable therapeutic approach for metastatic melanoma. The
aim of this study was to determine whether THC activates
cytotoxic autophagy in melanoma cells in vitro and in vivo.
Our data suggest a noncanonical mechanism of autophagy-
mediated apoptosis, highlighting the potential to harness
autophagy for therapeutic beneﬁt in advanced melanoma.
RESULTS
THC activates autophagy and apoptosis in melanoma cells
Characteristic features of early and late stages of autophagy
were assessed using LC3 lipidation (LC3-II) and analysis
of autophagic ﬂux using chloroquine and visualization of
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Figure 1. The Δ9-Tetrahydrocannabinol (THC) induces autophagy in melanoma cells. (a–c) A375, SK-MEL-28, and CHL-1 cells were treated with vehicle or THC
(4.5 or 5 μM) for 24 hours in the presence or absence of chloroquine (CQ; 10 μM) for the ﬁnal 2 hours, and LC3 and β-actin expression was determined by western
blotting. LC3-II expression was quantiﬁed and band intensity normalized to β-actin. Data are expressed as fold change relative to the mean LC3-II/β-actin value for
a representative experiment and are shown above the western blot (representative data from n=3 independent experiments). (d, e) mRFP–GFP–LC3 expressing
(d) A375 or (e) CHL-1 cells were treated with vehicle or THC (4.5 μM) for 18 hours. Data are representative ﬂuorescent micrographs (bar=20 μm) of three
independent experiments. (f) Total red ﬂuorescence values were generated from ≥20 cells per treatment condition, from two independent experiments. Pixel
intensities were divided by a factor of 106, and data are shown as mean± SD (**Po0.01 and ***Po0.001 vs. control for each cell line). mRFP–GFP, monomeric
red ﬂuorescent protein–green ﬂuorescent protein.
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tandem mRFP–GFP (monomeric red ﬂuorescent protein–
green ﬂuorescent protein)–tagged LC3 (Kimura et al., 2007),
respectively. LC3-II induction was observed in three human
melanoma cell lines in response to THC, and LC3-II
accumulated further in the presence of chloroquine in both
BRAF wild-type (CHL-1) and mutated (A375 and SK-MEL-28)
melanoma cells. In addition, increased numbers of LC3-
positive autophagosomes (yellow puncta) and autolysosomes
(red puncta) and total red ﬂuorescence (CHL-1: t43= 4.17,
Po0.001; A375: t42=3.289, P= 0.002) were observed in
A375 and CHL-1 cells in response to THC treatment,
indicating activation of autophagic ﬂux (Figure 1).
THC reduced melanoma cell viability in a dose-dependent
manner while having little effect on primary melanocytes at
doses up to 6 μM THC (Figure 2a). Cotreatment of melanoma
cells with submaximal concentrations of THC and the pan-
caspase inhibitor ZVAD-fmk signiﬁcantly increased cell
viability compared with treatment with THC alone (CHL-1:
t22= 3.962, P=0.0007; A375: t16=3.74, P=0.0018; Figure 2b),
suggesting that cell death is caspase dependent. In addition,
the cytochrome c–labeled structures present in vehicle-
treated cells were substantially reduced in THC-treated cells
(Figure 2c), indicating apoptosis activation.
THC-induced apoptosis is dependent on autophagy
In glioma, THC activates apoptosis via a mechanism involv-
ing TRIB3 and Beclin-1-dependent autophagy (Carracedo
et al., 2006; Salazar et al., 2009b). The small interfering RNA
(siRNA)-mediated knockdown of TRIB3 signiﬁcantly
prevented loss of cell viability in response to THC in A375
cells (one-way analysis of variance (ANOVA); F5, 48= 5.053,
P= 0.001; THC compared with vehicle treatment in siCtrl
cells; Tukey’s Po0.05; Supplementary Figure S1 online),
demonstrating that TRIB3 mediates THC-induced cell death.
Furthermore, siRNA-mediated knockdown of Atg7 prevented
THC-induced accumulation of LC3-II in the presence of
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Figure 2. The Δ9-Tetrahydrocannabinol (THC) induces apoptosis of melanoma cells. (a) Primary melanocytes, A375, and CHL-1 cells were treated with vehicle
or THC (3–10 μM) for 24 hours. (b) A375 (i) or CHL-1 (ii) cells were treated with vehicle or THC (5 μM) in the presence or absence of ZVAD (20 μM) for 24 hours.
Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data generated in triplicate were expressed
relative to the mean of vehicle-treated cells in each experiment, for three independent experiments, and shown as mean± SD (t-test; **Po0.01 and ***Po0.001
vs. THC+ZVAD). (c) A375 cells were treated with THC (5 μM) for 24 hours. Data are representative ﬂuorescent micrographs of cytochrome c immunostaining
(bar=20 μm) of three independent experiments.
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chloroquine (one-way ANOVA; F11, 24= 6.878, Po0.001;
chloroquine compared with chloroquine+THC-treated siCtrl
cells contrast Po0.05; Figure 3a and b). THC-induced
caspase 3 cleavage was also inhibited by Atg7 knockdown
in A375 (Figure 3a), as well as in CHL-1 and SK-MEL-28 cells
(CHL-1: one-way ANOVA; F5, 12=6.57, P= 0.004; THC
compared with vehicle-treated siCtrl cells; Tukey’s Po0.05;
SK-MEl-28: one-way ANOVA; F3, 8= 4.646, P= 0.037; THC
compared with vehicle-treated siCtrl cells; Tukey’s Po0.05;
Supplementary Figure S2 online). In addition, THC treatment
resulted in a signiﬁcant loss of melanoma cell viability only in
the absence of chloroquine or Atg7 siRNA (Figure 3 and
Supplementary Figure S2 online; post hoc tests, Games–
Howell, or Tukey’s Po0.01). In A375 and SK-MEL-28 cells,
knockdown of Atg7 alone had no effect on cell viability;
however, in CHL-1 cells, downregulation of Atg7 resulted in a
signiﬁcant loss of cell viability (Tukey’s Po0.001; Supple-
mentary Figure S2a online), suggesting that basal autophagy is
required to maintain viability in these cells. Collectively, these
data demonstrate that THC-induced apoptosis of melanoma
cells requires TRIB3 and is mediated by Atg7-dependent
autophagy.
Beclin-1 promotes autophagy induction and autophago-
some formation (Russell et al., 2013); however, Beclin-1-
independent autophagy has been reported (Scarlatti et al.,
2008; Grishchuk et al., 2011). Unlike in glioma cells, Beclin-1
knockdown did not prevent THC-induced LC3-II accumula-
tion or caspase 3 cleavage (t4=4.494, P= 0.011; Supple-
mentary Figure S3a online) in A375 cells (Figure 4a), and THC
treatment resulted in a signiﬁcant loss of cell viability under
both control and Beclin-1 knockdown conditions (Welch
ANOVA; F5, 19.63= 94.53, Po0.001; THC treatments com-
pared with vehicle-treated shRNA cells; Games–Howell
Po0.001; Figure 4a i) and ii)). These results suggest that
autophagy and subsequent apoptosis occur independently of
Beclin-1. Furthermore, knockdown of the Beclin-1-interacting
protein Ambra1 failed to prevent THC-induced LC3-II induction
and caspase 3 cleavage (t4=6.097, P= 0.004; Supplementary
Figure S3b online and Figure 4b). The effect of Ambra1
knockdown alone on A375 viability was variable; however,
THC treatment resulted in a signiﬁcant loss of cell viability
under both control (t16= 9.44, Po0.001) and Ambra1
knockdown conditions (t16= 10.61, Po0.001) (Figure 4biii).
Collectively, these data suggest that THC activates noncano-
nical autophagy-mediated apoptosis of melanoma cells that is
dependent on Atg7 but not Beclin-1 or Ambra1.
Cannabinoid treatment stimulates autophagy and apoptosis and
the abrogation of melanoma growth in vivo
A 1:1 mixture of submaximal doses of THC–botanical drug
substance (BDS) and the nonpsychoactive cannabinoid
cannabidiol (CBD) –BDS, a laboratory mimic of the clinical
cannabinoid Sativex (Sat-L) (an oromucosal spray of standar-
dized cannabis extract comprising equal amounts of THC and
CBD (GW Pharmaceuticals)), reduced glioma growth in vivo
to the same extent as an identical dose of THC (Torres et al.,
2011). Treatment of melanoma cells with THC+CBD resulted
in a substantial loss of melanoma cell viability at a
concentration of 1 μM THC+1 μM CBD in CHL-1, A375, and
SK-MEL-28 cells compared with equivalent concentrations of
THC, whereas temozolomide had little effect (Figure 5).
Temozolomide is an alkylating agent currently indicated as
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Figure 3. The Δ9-Tetrahydrocannabinol (THC)-induced apoptosis requires
autophagy. (a–c) A375 cells were transfected with small interfering RNAs
(siRNAs) for Atg7 (siAtg7) or with a nonsilencing control siRNA (siCtrl) before
treatment with vehicle or THC (4.5, 5 μM) for 24 hours in the presence or
absence of chloroquine (CQ; 10 μM) for the (a, b) ﬁnal 2 hours or for (c)
24 hours. (a, b) Atg7, LC3, cleaved caspase 3, and β-actin expression were
determined by western blotting. LC3-II expression was quantiﬁed and band
intensity normalized to β-actin. Data are expressed as fold change relative to
the mean LC3-II/β-actin value for each experiment, for three separate
experiments (mean± SD, n=3). (c) Cell viability was determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data
generated in triplicate were expressed relative to the mean of vehicle-treated
siCtrl cells in each experiment, for three independent experiments, and shown
as mean± SD (*Po0.05, **Po0.01, and ***Po0.001 vs. vehicle-treated siCtrl
cells).
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standard single-agent chemotherapy for metastatic mela-
noma. The in vivo relevance of these ﬁndings was evaluated
in the context of BRAF wild-type melanoma tumors, for which
there is a particular demand for novel therapeutic approach in
the absence of targeted therapies in this tumor group. CHL-1
xenograft tumors were treated for 20 days with temozolo-
mide, THC, or Sativex-L. Both THC and Sativex-L signiﬁcantly
inhibited the growth of xenografts (one-way ANOVA; F3,-
16= 9.347, P= 0.001; THC or Sat-L compared with vehicle,
Sat-L compared with Temozolomide: Po0.05, Figure 6a).
Tumors removed from animals at the time of killing were
processed for immunohistochemical analysis of proliferative
activity (Ki67), apoptosis (TUNEL), and autophagy (LC3). Ki67
ﬂuorescence differed signiﬁcantly between drug treatments
(Welch ANOVA; F3, 16.28= 61.363, Po0.001; Figure 6b) and
was signiﬁcantly reduced in tumors from animals treated with
temozolomide, THC, or Sativex-L compared with control
animals (Games–Howell; P≤ 0.001), as well as in tumors from
animals treated with THC or Sativex-L compared with those
treated with temozolomide (Games–Howell; Po0.001).
TUNEL ﬂuorescence also differed signiﬁcantly between
treatments (one-way ANOVA; F3, 32= 13.31, Po0.001) and
was higher than control in tumors from animals treated with
THC or Sativex-L (Tukey’s P≤ 0.001) and higher in tumors
from animals treated with Sativex-L compared with those
treated with temozolomide (Tukey’s Po0.05; Figure 6c).
Correspondingly, LC3 ﬂuorescence differed between treat-
ments (one-way ANOVA; F3, 32= 3.539, Po0.05), with
signiﬁcantly increased LC3 staining in tumors from animals
treated with Sativex-L compared with tumors from animals
treated with vehicle or temozolomide (Tukey’s P≤ 0.05,
Figure 6d). Staining for Ki67, TUNEL, and LC3 was not signi-
ﬁcantly different in tumors from animals treated with THC
compared with Sativex-L. Collectively, these data suggest that
THC and Sativex-L are more effective than temozolomide in
terms of apoptosis induction and antitumor response, further
validating the therapeutic relevance of cannabinoid treatment
for melanoma.
DISCUSSION
It is apparent that autophagy modulation may offer consider-
able beneﬁt in cancer treatment; however, potential draw-
backs to autophagy inhibition have recently been identiﬁed
(Michaud et al., 2011; Maycotte et al., 2012; Takahashi et al.,
2012; Rosenfeldt et al., 2013). Emerging evidence indicates
that activation of autophagy can, in some circumstances,
promote cell death; stimulation of cytotoxic autophagy therefore
represents an alternative approach to autophagy modulation
(Ding et al., 2007; Scarlatti et al., 2008; Salazar et al., 2009b;
Grishchuk et al., 2011; Tomic et al., 2011; Basit et al., 2013).
Here, we show that the cannabinoid THC exerts its antitumor
effect on melanoma cells via activation of noncanonical
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Figure 4. The Δ9-Tetrahydrocannabinol (THC)-induced autophagy and cell death is not dependent on Beclin-1 or Ambra1. (a) A375 cells stably expressing
short hairpin RNA (shRNA) for Beclin-1 (shBeclin1) or a nonsilencing control shRNA (shCtrl) were treated with vehicle or THC (4.5 and 5 μM) for 48 hours in the
presence or absence of chloroquine (CQ; 10 μM) for the ﬁnal 2 hours (i). Beclin-1, LC3, cleaved caspase 3, and β-actin expression were determined by western
blotting (i). Cell viability (ii) was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data generated in triplicate were
expressed relative to the mean of vehicle-treated shCtrl cells in each experiment, for three independent experiments, and shown as mean± SD (***Po0.001 vs.
vehicle-treated shCtrl cells). (b) A375 cells stably expressing shRNA for Ambra1 (shAmbra1) or a nonsilencing control shRNA (shCtrl) were treated with vehicle or
THC (5 μM) for 24 hours in the presence or absence of CQ (10 μM) for the ﬁnal 2 hours (i). Ambra1, LC3, cleaved caspase 3, and β-actin expression were
determined by western blotting (i). Cell viability (ii) was determined by the MTT assay. Data generated in triplicate were normalized to the mean of vehicle-treated
cells for each shRNA in each experiment, for three independent experiments, and shown as mean± SD (***Po0.001 vs. vehicle-treated cells for each shRNA).
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autophagy and subsequent apoptosis, suggesting that canna-
binoids may be of clinical beneﬁt for metastatic melanoma.
The molecular mechanisms connecting autophagy to cell
death remain poorly understood (Shen and Codogno, 2011);
however, reports describing autophagy-dependent apoptosis
(Ding et al., 2007; Salazar et al., 2009b; Grishchuk et al.,
2011; Tomic et al., 2011) suggest multiple interactions
between autophagic and apoptotic machinery. THC exerts
its effect via the de novo synthesis of the sphingolipid cera-
mide, leading to the activation of ER stress, TRIB3-dependent
inhibition of Akt/mTORC1 signaling, and autophagy-mediated
apoptosis (Carracedo et al., 2006; Salazar et al., 2009b).
TRIB3 has been identiﬁed as a key switch between cell survival
and apoptosis during stress responses (Shimizu et al., 2012),
and the participation of TRIB3 in the melanoma response to
THC may direct cellular fate toward apoptosis in the context of
ER stress–induced autophagy (Salazar et al., 2013).
Autophagy inhibition using both molecular and pharmaco-
logical approaches prevented THC-induced autophagy and
apoptosis of melanoma cells. However, THC-induced autop-
hagy was not prevented by knockdown of Beclin-1, suggest-
ing that, in contrast to glioma, noncanonical autophagy
mediates apoptosis in response to THC in melanoma. Beclin-
1-independent autophagy may promote caspase-independent
cell death (Scarlatti et al., 2008; Basit et al., 2013) as well as
apoptosis (Grishchuk et al., 2011; Tomic et al., 2011),
suggesting that autophagy mechanisms not involving
Beclin-1 exist that interact with cell death machinery. Interest-
ingly, in contrast to previous studies (Salazar et al., 2009b),
THC-induced autophagy was also independent of Ambra1 in
melanoma cells. Ambra1 is a Beclin-1 interacting protein that
promotes autophagy by stabilizing Beclin-1 complexes (Fimia
et al., 2007); although supporting the concept of Beclin-1-
independent autophagy activation in response to THC, these
data highlight the complex regulation of autophagy that likely
occurs in a cell type- and context-speciﬁc manner.
Tumor-selective killing can be achieved by targeting
pathways that are differentially regulated in cancer cells
compared with normal cells. In this respect, we have shown
that normal human melanocytes are resistant to THC at
concentrations that cause cell death in melanoma cells. This
is consistent with studies showing that cancerous cells are
more sensitive to THC and other cannabinoid receptor ligands
compared with their nontransformed counterparts, despite the
presence of functional CB receptors (Velasco et al., 2012).
Together with previous studies demonstrating an effect of
synthetic ligands of cannabinoid receptors in melanoma
(Blazquez et al., 2006), these data support clinical evaluation
of cannabinoids in advanced-stage disease. Furthermore,
THC activates autophagy and apoptosis in both BRAF wild-
type and mutated melanoma cell lines, suggesting that despite
autophagy deregulation (Armstrong et al., 2011; Corazzari
et al., 2013), THC is likely effective in melanoma tumors
regardless of BRAF mutation status. Furthermore, our ﬁndings
show that THC is able to reduce melanoma cell viability and
tumor xenograft growth alone, but when lower doses of THC
are combined with CBD the antitumor effect was enhanced
in vitro and was at least equally effective as the higher dose of
single-agent THC in vivo. Moreover, CBD induces apoptosis
via the production of reactive oxygen species and caspase
activation in cancer cells (Massi et al., 2006; Shrivastava
et al., 2011), indicating that THC and CBD engage different
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Figure 5. Cannabinoids inhibit melanoma cell viability in vitro. (a–c) CHL-1
(a), A375 (b), or SK-MEL-28 (c) cells were treated with temozolomide (Temo;
10–50 μM), Δ9-Tetrahydrocannabinol (THC; 1–5 μM), or THC+CBD (0.5 μM
THC+0.5 μM CBD to 2.5 μM THC+2.5 μM CBD) for 48 hours. Cell viability was
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Data generated in triplicate were expressed relative to
the mean of vehicle-treated cells for each drug treatment in each experiment,
for three independent experiments, and shown as mean± SD for a
representative experiment. CBD, cannabidiol.
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molecular machineries that cooperate to promote tumor cell
death (Shrivastava et al., 2011; Torres et al., 2011).
In summary, these data highlight the potential for
cannabinoid-induced cytotoxic autophagy as an effective
strategy to drive melanoma cell death, supporting the clinical
evaluation of Sativex for the treatment of metastatic disease.
MATERIALS AND METHODS
Cell culture, viability assays, and drug treatment
Melanoma cell lines CHL-1, A375, and SK-MEL-28 were obtained
from the ATCC (Manassas, VA) in 2006 and cultured as described
previously (Armstrong et al., 2007). Cell lines were veriﬁed by melan
A staining (Flockhart et al., 2009) with B-RAF/NRASmutational status
conﬁrmed using Custom TaqMan SNP genotyping assays (Hiscutt
et al., 2010) (Applera Europe BV, Life Technologies, Paisley, UK) (last
tested February 2014). Before drug treatment, culture medium was
changed to 0.5% fetal bovine serum medium. Temozolomide (OSI
Pharmaceuticals, Melville, NY) and ZVAD-fmk (benzyloxycarbonyl-
V-A-D(OMe)-ﬂuoromethylketone) (Tocris Bioscience, Bristol, UK)
were added in DMSO, and chloroquine (Sigma-Aldrich Ltd, Poole,
UK) was added in water. For in vitro experiments, pure THC (THC
Pharm, Frankfurt, Germany) and CBD (synthesized by Professor Raphael
Mechoulam (Hebrew University of Jerusalem) and kindly provided by
Dr Javier Fernandez Ruiz (Complutense University, Madrid, Spain))
were prepared in DMSO. Control incubations contained the same
amount of DMSO (0.1–0.2% v/v). For treatment with THC+CBD, pure
THC and pure CBD were mixed 1:1 (w/w). Analysis of cell viability was
performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT; Sigma). For in vivo experiments, THC–BDS (THC
content 67.6% w/w; CBD content 0.3% w/w; other individual plant
cannabinoids o1.5% w/w) and CBD–BDS (CBD content 65.4% w/w;
THC content 2.5% w/w; other individual plant cannabinoidso1.7% w/
w) were provided by GW Pharmaceuticals (Cambridge, UK). THC–BDS
and CBD–BDS were provided as a resin, dissolved in ethanol (100
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Figure 6. The Δ9-Tetrahydrocannabinol (THC) and Sativex-like cannabinoids promote autophagy and antitumor responses in melanoma xenografts. Athymic
nude mice were injected subcutaneously in the right ﬂank with CHL-1 melanoma cells. When tumors reached a 250mm3 size, mice were treated daily for
20 days with vehicle, temozolomide (TMZ; 5 mg kg−1; local administration), THC (15mg kg−1; oral administration), or Sativex-like (Sat-L; 7.5 mg kg−1
THC–BDS+7.5 mg kg−1 CBD–BDS; oral administration). (a) Tumor volumes were measured daily. Each point is the mean from ≥5 tumors± SD and is expressed
relative to the tumor volume on day 1 of treatment. (b–d) Immunohistochemical analysis of CHL-1 xenograft tumors treated with temozolomide, THC, or Sat-L.
(b–d) Micrographs of tumor sections stained for (b) Ki67, (c) TUNEL, or (d) LC3. In each, green is staining for Ki67, TUNEL, or LC3, and red is the TO-PRO-3
counterstain. The bar graphs below each set of micrographs summarize the data analysis from tumor sections (bar=20 μm). Total ﬂuorescence values (total
ﬂuorescence (LC3/Ki67/TUNEL)/total nuclear ﬂuorescence) were generated in triplicate for 3 tumors in each treatment group. Data are expressed as fold change
relative to the mean value obtained from control animals, from two independent staining analyses, and shown as mean± SD (**Po0.01 and ***Po0.001 vs.
control animals).
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mgml−1), dried, and prepared in DMSO. A 1:1 (w/w) preparation of
THC–BDS and CBD–BDS was used to mimic Sativex (Sat-L). For oral
administration, THC or Sat-L was solved in 100 μl of sesame oil.
Western blotting and reverse transcription–PCR analysis
Preparation of whole-cell lysates and western blotting for LC3B, cleaved
caspase 3 (Cell Signaling Technology, Leiden, The Netherlands), Atg7
(Santa Cruz Biotechnology, Heidelberg, Germany), Beclin-1 (BD
Biosciences, Oxford, UK), and Ambra1 (Novus Biologicals, Cambridge,
UK) all diluted 1:4,000, and β-actin (Sigma) diluted 1:30,000, were
performed as described previously (Armstrong et al., 2007). Total RNA
was isolated from cells using the RNeasy Mini Kit with DNase digestion
(Qiagen, Manchester, UK) according to the manufacturer’s protocol.
Reverse transcription–PCR was performed using the Access Reverse
transcription–PCR system (Promega, Southampton, UK) using primers
for TRIB3 (Carracedo et al., 2006) or β-actin (Armstrong et al., 2005).
PCR products were analyzed by electrophoresis on ethidium bromide–
stained 2% agarose gels and DNA visualized by exposure to UV light.
siRNA transfections
The siRNA for Atg7 (HSS116182), TRIB3 (sc-44426, Santa Cruz
Biotechnology), or a nontargeting siRNA (Negative control Low GC
Stealth RNAi) (Stealth RNAi, Life Technologies, Paisley, UK) were
transfected into cells in OPTIMEM containing siRNA (2–4 nM) using
Lipofectamine RNAiMAX (Life Technologies) according to the
manufacturer’s speciﬁcation for reverse transfection. After 24 hours,
the medium was replaced with DMEM containing 0.5% fetal bovine
serum and cells treated with drugs as appropriate.
Retroviral or lentiviral infection
Retroviral expression of mRFP–GFP–LC3 (provided by T Yoshimori,
Osaka University, Osaka, Japan) (Kabeya et al., 2000; Kimura et al.,
2007) was performed as described previously (Armstrong et al., 2011).
Lentiviral expression of shAmbra1 or a nontargeting sequence shCtrl
(MISSION shRNA, Sigma) was performed by cotransfection of 7.5 μg
lentivirus vector (pLKO.1-puro) with 2.5 μg of an expression plasmid for
the vesicular stomatitis virus G protein into 293 cells using the calcium
precipitation method. After 48 hours, melanoma cells were incubated
with virus-containing supernatant supplemented with polybrene
(4 μgml−1) for 6–8 hours and selected for puromycin resistance.
Lentiviral expression of shBeclin-1 (V3LHS_349509, Dharmacon,
Chalfont St Giles, UK) or a nontargeting sequence shCtrl (RHS4346,
Dharmacon) was performed by cotransfection of 20 μg lentivirus vector
with 5 μg of an expression plasmid for the viral envelope (pMD2.G)
and 15 μg packaging plasmid (pCMVdelta8.91) into HEK293T cells
using the calcium precipitation method. After 72 hours, melanoma cells
were spin transduced (1.5 hours, 1,200 r.p.m., Harrier 15/80, DJB
Labcare, Newport Pagnell, UK) with virus-containing supernatant
supplemented with polybrene (4 μgml−1) and selected for puromycin
resistance.
Confocal microscopy
Cells were grown on glass coverslips before ﬁxation in 4%
paraformaldehyde. For immunolabeling, cells were incubated with
0.2% Triton X-100 before incubation with anti-cytochrome c (BD
Biosciences) at room temperature for 1 hour (McGill et al., 2005).
Secondary labeling was performed with Oregon Green 488 con-
jugated to anti-rabbit IgG (Life Technologies). Nuclei were
counterstained with TO-PRO-3 iodide (Life Technologies). Cells
were imaged under a Leica TCS SP II laser-scanning confocal
microscope with LCS Lite 2.61 software (Leica Microsystems, Milton
Keynes, UK), using a 63× oil objective.
Xenograft mouse model and immunohistochemical analysis
Athymic nude (nu/nu) 5-week-old male mice (Harlan Iberica
Laboratory, Madrid, Spain) were inoculated by subcutaneous injection
of 7.5×106 CHL-1 cells in 100 μl phosphate-buffered saline containing
0.1% glucose. On establishment of tumors 250mm3 in volume, mice
were randomized into four treatment groups (5–8 mice per group) and
treated by daily administration for 20 days with temozolomide (5
mg kg−1, local peritumoral injection), THC (15mg kg−1, oral gavage),
or Sativex (7.5mg kg−1 THC–BDS+7.5mg kg−1 CBD–BDS, oral
gavage). The control group was treated with 100 μl of vehicle (sesame
oil). Caliper measurements of tumor length (l) and width (w) were taken
each day, and tumor volume was calculated as (4π/3)× (w/2)2× (l/2).
Mice were humanely killed on the ﬁnal day of treatment, and tumors
extracted and snap frozen in liquid nitrogen before storage at −80 °C.
Frozen sections (6 μm) prepared on (3-Aminopropyl)triethoxysilane
(Sigma)-coated glass slides were ﬁxed in 4% paraformaldehyde before
staining by TUNEL or with a Ki67 antibody (ab-15580, Abcam,
Cambridge, UK) as previously described (Hill et al., 2009). For LC3
immunolabeling, frozen sections were ﬁxed in acetone and incubated
with anti-LC3B (ab48394, Abcam) for 1 hour at room temperature.
Secondary labeling was performed with Oregon Green 488 conjugated
to anti-rabbit IgG (Life Technologies). Cells were imaged under a Leica
TCS SP II laser-scanning confocal microscope with LCS Lite 2.61
software (Leica Microsystems), using a 63×oil objective. All proce-
dures involving animals were performed according to Spanish and
European regulations and were approved by the ethical committee for
animal experimentation from Complutense University.
Statistical analysis
Images of LC3, Ki67, and TUNEL staining were analyzed using
Velocity (v4.3.1) (Improvision, Perkin Elmer, Coventry, UK). Total
ﬂuorescence was obtained by multiplying pixel number to the mean
pixel intensity, after appropriate thresholding. TOPRO-3 ﬂuorescence
was determined by the number of pixels with ﬂuorescence above the
threshold, which was proportional to nuclei number. For each tumor
(three animals per group, three randomly selected images each),
values were reported as normalized total ﬂuorescence (total
ﬂuorescence (LC3/Ki67/TUNEL)/total nuclear ﬂuorescence) and
expressed as fold change relative to the mean value obtained from
control animals, from two independent staining analyses. The mRFP
ﬂuorescence was analyzed using ImageJ (public domain licence,
http://imagej.nih.gov/ij/); data are total pixel intensities/cell minus the
mean background ﬂuorescence of nuclei. Homogeneity of variances
was checked using Levene’s test, and if variances were equal
(normalized data or after log transformation) data were analyzed by
drug treatment using Student’s t-test or one-way ANOVA with planned
contrasts (LC3 expression) or Tukey’s post hoc test for multiple pair-
wise comparisons. Where variances were not equal, Welch ANOVA
test was used with Games–Howell post hoc tests for pair-wise
comparisons (SPSS Statistics 20, SPSS, IBM, Portsmouth, UK).
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